Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Propsci Perspectives: LabCentral/BioLabs

Related Content

2026 HSR Thresholds Announced: $133.9 million

Year in Review: Big Deals of 2025

Life Sciences Capital Markets: Preparing for Your 2026 IPO

The New Playbook for Competitive Life Sciences M&A — How Buyers Can Differentiate Beyond Price Through Structure and Strategy

Celltrion and Sandoz Launch Their Aflibercept Biosimilars in Europe

Sun Pharma Launches ILUMYA® in India

FDA Approves mAbxience and Amneal’s Denosumab Biosimilars

Biocon and Regeneron Enter Global Settlement on Aflibercept Biosimilar

Goodwin Advises Aktis Oncology in Closing of $365.4 Million Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Goodwin Advises Vibrant Therapeutics in Raising $61 Million

Goodwin Advises SciNeuro in Entering into a Licensing and Collaboration Agreement with Novartis for $165 Million Upfront and Up to $1.5 Billion in Milestones

Goodwin Guides Monte Rosa Therapeutics in Pricing of $300 Million Underwritten Public Offering

Goodwin Advises Noetik in Licensing AI Foundation Models in Anchor Partnership with GSK

Goodwin Represents Nimbus Therapeutics in Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment for Up to $1.3 Billion

Goodwin Guides Parabilis Medicines in Oversubscribed $305 Million Financing

Goodwin Advises Corsera Health on $80 Million Series A Financing

Life Sciences